Phase II Study Of S-1, Oral Leucovorin, Oxaliplatin and Bevacizumab Combination Therapy (SOL + BV; SOLA) in Patients with Unresectable Metastatic Colorectal Cancer (MCRC)

Phase Ii ◽

Phase Ii Study ◽

A phase II study of S-1, oxaliplatin, oral leucovorin, and bevacizumab combination therapy (SOLA) in patients with unresectable metastatic colorectal cancer

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-015-2825-5 ◽

2015 ◽

Vol 76 (3) ◽

pp. 547-553 ◽

Cited By ~ 4

Author(s):

Tomohiro Nishina ◽

Takeshi Kato ◽

Kentaro Yamazaki ◽

Takayuki Yoshino ◽

Yoshinori Miyata ◽

...

Keyword(s):

Colorectal Cancer ◽

Combination Therapy ◽

Phase Ii ◽

Phase Ii Study ◽

PEAK: A randomized phase II study to compare the efficacy of panitumumab plus mFOLFOX6 to bevacizumab plus mFOLFOX6 in patients (pts) with previously untreated, unresectable metastatic colorectal cancer (mCRC) expressing wild-type KRAS.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.tps189 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. TPS189-TPS189

Author(s):

L. S. Schwartzberg ◽

V. J. Wagner

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Wild Type ◽

Randomized Phase Ii ◽

6118 POSTER Randomized Phase II Study of S-1, Oral Leucovorin, and Oxaliplatin Combination Therapy (SOL) Versus MFOLFOX6 in Patients With Untreated Metastatic Colorectal Cancer (mCRC)

European Journal of Cancer ◽

10.1016/s0959-8049(11)71763-4 ◽

2011 ◽

Vol 47 ◽

pp. S427-S428

Author(s):

H. Ojima ◽

K. Yamazaki ◽

H. Kuwano ◽

T. Otsuji ◽

T. Kato ◽

...

Keyword(s):

Colorectal Cancer ◽

Combination Therapy ◽

Phase Ii ◽

Phase Ii Study ◽

Randomized Phase Ii

469P Efficacy and safety of anlotinib combined with CAPEOX in first-line treatment of patients with RAS and BRAF wild-type unresectable metastatic colorectal cancer - A single-arm, multi-center, phase II study (ALTER-C-002 trial)

Annals of Oncology ◽

10.1016/j.annonc.2020.08.580 ◽

2020 ◽

Vol 31 ◽

pp. S440

Author(s):

K. Ding ◽

Y. Liu ◽

J. Chen ◽

J. Ying ◽

Q. Xu ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Line Treatment ◽

Efficacy And Safety ◽

Wild Type ◽

First Line ◽

First Line Treatment ◽

Phase II study evaluating trifluridine/tipiracil + bevacizumab and capecitabine + bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are non-eligible for intensive therapy (TASCO1): Results of the primary analysis

Annals of Oncology ◽

10.1093/annonc/mdy149.021 ◽

2018 ◽

Vol 29 ◽

pp. v108 ◽

Cited By ~ 5

Author(s):

K. Lesniewski-Kmak ◽

V. Moiseenko ◽

M. Saunders ◽

H. Wasan ◽

G. Argiles ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Intensive Therapy ◽

First Line ◽

Primary Analysis ◽

AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer

BMC Cancer ◽

10.1186/s12885-020-07169-6 ◽

2020 ◽

Vol 20 (1) ◽

Cited By ~ 1

Author(s):

Carlotta Antoniotti ◽

Beatrice Borelli ◽

Daniele Rossini ◽

Filippo Pietrantonio ◽

Federica Morano ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Initial Therapy ◽

Phase II Study of Ensituximab, a Novel Chimeric Monoclonal Antibody, in Adults with Unresectable, Metastatic Colorectal Cancer

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-20-0426 ◽

2020 ◽

Vol 26 (14) ◽

pp. 3557-3564

Author(s):

Richard D. Kim ◽

Nilofer S. Azad ◽

Michael A. Morse ◽

Elizabeth Poplin ◽

Amit Mahipal ◽

...

Keyword(s):

Colorectal Cancer ◽

Monoclonal Antibody ◽

Phase Ii ◽

Phase Ii Study ◽

Chimeric Monoclonal Antibody ◽

Multicenter Phase II Study of FOLFOX6 for Previously Untreated Unresectable Metastatic Colorectal Cancer

Journal of Integrative Oncology ◽

10.4172/2329-6771.1000120 ◽

2014 ◽

Vol 03 (02) ◽

Cited By ~ 1

Author(s):

Satoru Iwasa

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Multicenter Phase ◽

TRIUMPH Study: A multicenter Phase II study to evaluate efficacy and safety of combination therapy with trastuzumab and pertuzumab in patients with HER2-positive metastatic colorectal cancer (EPOC1602)

Annals of Oncology ◽

10.1093/annonc/mdx393.137 ◽

2017 ◽

Vol 28 ◽

pp. v207 ◽

Cited By ~ 3

Author(s):

Y. Nakamura ◽

W. Okamoto ◽

K. Sawada ◽

Y. Komatsu ◽

K. Kato ◽

...

Keyword(s):

Colorectal Cancer ◽

Combination Therapy ◽

Phase Ii ◽

Phase Ii Study ◽

Efficacy And Safety ◽

Her2 Positive ◽

Multicenter Phase

A randomized phase II study of combination therapy with S-1, oral leucovorin, and oxaliplatin (SOL) and mFOLFOX6 in patients with previously untreated metastatic colorectal cancer

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-015-2676-0 ◽

2015 ◽

Vol 75 (3) ◽

pp. 569-577 ◽

Cited By ~ 15

Author(s):

Kentaro Yamazaki ◽

Hiroyuki Kuwano ◽

Hitoshi Ojima ◽

Toshio Otsuji ◽

Takeshi Kato ◽

...

Keyword(s):

Colorectal Cancer ◽

Combination Therapy ◽

Phase Ii ◽

Phase Ii Study ◽

Randomized Phase Ii